Clinical Trial News

A new DHODH inhibitor, HOSU-53, developed at The Ohio State University, will undergo a clinical trial for cancer treatment, targeting key cellular metabolic processes essential for cancer growth.

GLP-1 receptor agonists significantly reduce cirrhosis progression and complications in patients with metabolic dysfunction-associated steatotic liver disease, according to a study in JAMA Internal Medicine. The study, based on over 16,000 patients, found a 14% reduction in cirrhosis risk and lower risks of complications and mortality. These findings suggest potential preventive treatment for cirrhosis in diabetes and MASLD patients.

After my wife's successful breast cancer treatment at MD Anderson, I was diagnosed with acute myeloid leukemia in 2018 and also treated there, achieving remission. MD Anderson corrected my initial diagnosis, and I participated in a successful clinical trial. The personalized care was exceptional, leading me to join the Boot Walk to End Cancer, raising funds and awareness. My family supports this effort, and we are grateful for the extended life experiences MD Anderson has enabled.

Endomimetics awarded $2.8M SBIR grant to research Bionanomatrix™ coating for flow diverters in treating brain aneurysms, aiming to accelerate endothelialization and reduce thromboembolic risks.

FDA grants Breakthrough Therapy Designation to BridgeBio's infigratinib for achondroplasia, based on PROPEL 2 trial data showing significant AHV increase and body proportionality improvement. PROPEL 3 Phase 3 study is enrolling, aiming for first-in-class oral therapeutic option.

Solid tumors market projected to reach $375.4B by 2034 with 7.45% CAGR. Aethlon Medical activates Hemopurifier trial at Royal Adelaide Hospital for solid tumor patients resistant to anti-PD-1 therapies. Immuneering reports positive initial data for IMM-1-104 in pancreatic cancer. FDA approves new immunotherapy combinations for endometrial cancer from AstraZeneca, Merck, and GlaxoSmithKline. Roche's trastuzumab deruxtecan receives accelerated approval for HER2-positive solid tumors.

Rocket Pharmaceuticals, Inc. announces full enrollment in global Phase 2 trial evaluating RP-A501 for Danon disease, aiming for regulatory filings in the U.S. and ex-U.S.

TransCode Therapeutics announces dosing of first two patients in Phase 1 trial for TTX-MC138, an antisense oligonucleotide targeting microRNA-10b to treat metastatic cancer. Several additional patients are being screened for enrollment in the multicenter, open-label study evaluating safety and tolerability.

Guard Therapeutics' phase 2 AKITA study with RMC-035, targeting kidney injury post-open-heart surgery, showed significant kidney-protective effects, published in eClinicalMedicine. The study's results support the ongoing phase 2b POINTER study and future phase 3 development.

Poseida Therapeutics announced FDA's RMAT designation for P-BCMA-ALLO1, an allogeneic CAR-T therapy in phase 1/1b for relapsed/refractory multiple myeloma, based on early promising data. The designation includes Fast Track and Breakthrough Therapy benefits, facilitating early FDA interactions. Poseida plans to report new clinical data at the 21st International Myeloma Society Annual Meeting in 2024.